| Style | Citing Format |
|---|---|
| MLA | Mirmosayyeb O, et al.. "Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis." Autoimmunity Reviews, vol. 20, no. 2, 2021, pp. -. |
| APA | Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M (2021). Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 20(2), -. |
| Chicago | Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M. "Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis." Autoimmunity Reviews 20, no. 2 (2021): -. |
| Harvard | Mirmosayyeb O et al. (2021) 'Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis', Autoimmunity Reviews, 20(2), pp. -. |
| Vancouver | Mirmosayyeb O, Shaygannejad V, Barzegar M, Nehzat N, Ghajarzadeh M. Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis. Autoimmunity Reviews. 2021;20(2):-. |
| BibTex | @article{ author = {Mirmosayyeb O and Shaygannejad V and Barzegar M and Nehzat N and Ghajarzadeh M}, title = {Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis}, journal = {Autoimmunity Reviews}, volume = {20}, number = {2}, pages = {-}, year = {2021} } |
| RIS | TY - JOUR AU - Mirmosayyeb O AU - Shaygannejad V AU - Barzegar M AU - Nehzat N AU - Ghajarzadeh M TI - Efficacy and Safety of Rituximab in Treating Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Systematic Review and Meta-Analysis JO - Autoimmunity Reviews VL - 20 IS - 2 SP - EP - PY - 2021 ER - |